Robin Jones to Antineoplastic Agents, Alkylating
This is a "connection" page, showing publications Robin Jones has written about Antineoplastic Agents, Alkylating.
Connection Strength
2.588
-
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
Score: 0.755
-
Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
Score: 0.674
-
Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun; 30(2):501.
Score: 0.428
-
Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. Expert Rev Anticancer Ther. 2018 12; 18(12):1241-1248.
Score: 0.158
-
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.
Score: 0.144
-
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
Score: 0.128
-
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011 Dec; 123(3):553-6.
Score: 0.097
-
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul; 8(7):595-602.
Score: 0.072
-
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 06 01; 28(11):2306-2312.
Score: 0.051
-
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Rev Anticancer Ther. 2020 04; 20(sup1):15-28.
Score: 0.044
-
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
Score: 0.037